[1]
Ghosh, S.; Banerjee, S.; Sil, P.C. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food Chem. Toxicol., 2015, 83, 111-124.
[2]
Hurley, L.L.; Tizabi, Y. Neuroinflammation, neurodegeneration, and depression. Neurotox. Res., 2013, 23(2), 131-144.
[3]
Ryan, S.M.; Nolan, Y.M. Neuroinflammation negatively affects adult hippocampal neurogenesis and cognition: can exercise compensate? Neurosci. Biobehav. Rev., 2015, 61, 121-131.
[4]
Lyman, M.; Lloyd, D.G.; Ji, X.; Vizcaychipi, M.P.; Ma, D. Neuroinflammation: The role and consequences. Neurosci. Res., 2014, 79, 1-12.
[5]
Carriba, P.; Comella, J.X. Neurodegeneration and neuroinflammation: two processes, one target. Neural Regen. Res., 2015, 10(10), 1581-1583.
[6]
Deguchi, A. Curcumin targets in inflammation and cancer. Endocr. Metab. Immune Disord. Drug Targets, 2015, 15(2), 88-96.
[7]
Shishodia, S. Molecular mechanisms of curcumin action: Gene expression. Biofactors, 2013, 39(1), 37-55.
[8]
Shehzad, A.; Rehman, G.; Lee, Y.S. Curcumin in inflammatory diseases. Biofactors, 2013, 39(1), 69-77.
[9]
Chen, W.W.; Zhang, X.; Huang, W.J. Role of neuroinflammation in neurodegenerative diseases (Review). Mol. Med. Rep., 2016, 13(4), 3391-3396.
[10]
Gao, H-M.; Hong, J-S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol., 2008, 29(8), 357-365.
[11]
Brites, D.; Fernandes, A. Neuroinflammation and depression: Microglia activation, extracellular microvesicles and microRNA dysregulation. Front. Cell. Neurosci., 2015, 9, 476.
[12]
Kopitar-Jerala, N. Innate immune response in brain, NF-Kappa B signaling and cystatins. Front. Mol. Neurosci., 2015, 8, 73.
[13]
Klos, A.; Wende, E.; Wareham, K.J.; Monk, P.N. International union of basic and clinical pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev., 2013, 65(1), 500-543.
[14]
Scapagnini, G.; Vasto, S.; Abraham, N.G.; Caruso, C.; Zella, D.; Fabio, G. Modulation of Nrf2/ARE pathway by food polyphenols: A nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol. Neurobiol., 2011, 44(2), 192-201.
[15]
Dumont, M.; Wille, E.; Calingasan, N.Y.; Tampellini, D.; Williams, C.; Gouras, G.K.; Liby, K.; Sporn, M.; Flint Beal, M.; Lin, M.T. Triterpenoid CDDO‐methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer’s disease. J. Neurochem., 2009, 109(2), 502-512.
[16]
Kalyanaraman, B. Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms. Redox Biol., 2013, 1(1), 244-257.
[17]
Szabó, C.; Ischiropoulos, H.; Radi, R. Peroxynitrite: Biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov., 2007, 6(8), 662-680.
[18]
Kothur, K.; Wienholt, L.; Brilot, F.; Dale, R.C. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review. Cytokine, 2016, 77, 227-237.
[19]
Ray, B.; Lahiri, D.K. Neuroinflammation in Alzheimer’s disease: Different molecular targets and potential therapeutic agents including curcumin. Curr. Opin. Pharmacol., 2009, 9(4), 434-444.
[20]
Khairova, R.A.; Machado-Vieira, R.; Du, J.; Manji, H.K. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int. J. Neuropsychopharmacol., 2009, 12(4), 561-578.
[21]
Leonard, B.E. Inflammation, depression and dementia: Are they connected? Neurochem. Res., 2007, 32(10), 1749-1756.
[22]
Vojdani, A.; Lambert, J. The role of Th17 in neuroimmune disorders: target for CAM therapy. Part I. Evid. Based Complement. Alternat. Med., 2011, 2011, 927294.
[23]
Morales, I.; Guzman-Martinez, L.; Cerda-Troncoso, C.; Farias, G.A.; Maccioni, R.B. Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. Front. Cell. Neurosci., 2014, 8, 112.
[24]
Aggarwal, B.B.; Sundaram, C.; Malani, N.; Ichikawa, H. Curcumin: The Indian solid gold. In: The molecular targets and therapeutic uses of curcumin in health and disease; Springer, 2007; pp. 1-75.
[25]
Kim, D.S.; Kim, J.Y.; Han, Y. Curcuminoids in neurodegenerative diseases. Recent Patents CNS Drug Discov., 2012, 7(3), 184-204.
[26]
Priyadarsini, K.I. Photophysics, photochemistry and photobiology of curcumin: Studies from organic solutions, bio-mimetics and living cells. J. Photochem. Photobiol. C. Photochem. Rev., 2009, 10(2), 81-95.
[27]
Galano, A.; Álvarez-Diduk, R.; Ramírez-Silva, M.T.; Alarcón-Ángeles, G.; Rojas-Hernández, A. Role of the reacting free radicals on the antioxidant mechanism of curcumin. Chem. Phys., 2009, 363(1-3), 13-23.
[28]
Yanagisawa, D.; Shirai, N.; Amatsubo, T.; Taguchi, H.; Hirao, K.; Urushitani, M.; Morikawa, S.; Inubushi, T.; Kato, M.; Kato, F.; Morino, K.; Kimura, H.; Nakano, I.; Yoshida, C.; Okada, T.; Sano, M.; Wada, Y.; Wada, K-N.; Yamamoto, A.; Tooyama, I. Relationship between the tautomeric structures of curcumin derivatives and their Aβ-binding activities in the context of therapies for Alzheimer’s disease. Biomaterials, 2010, 31(14), 4179-4185.
[29]
(a) Ghalandarlaki, N.; Alizadeh, A.M.; Ashkani-Esfahani, S. Nanotechnology-applied curcumin for different diseases therapy. BioMed Res. Int., 2014, 2014, 394264.
(b) Li, Y.; Wang, P. [Neuroprotective effects of curcumin]. Zhongguo Zhongyao Zazhi, 2009, 34(24), 3173-3175.
[30]
Singh, R.; Sharma, P. Hepatoprotective effect of curcumin on lindane-induced oxidative stress in male Wistar rats. Toxicol. Int., 2011, 18(2), 124-129.
[31]
Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41(1), 40-59.
[32]
Hurley, L.L.; Akinfiresoye, L.; Nwulia, E.; Kamiya, A.; Kulkarni, A.A.; Tizabi, Y. Antidepressant-like effects of curcumin in WKY rat model of depression is associated with an increase in hippocampal BDNF. Behav. Brain Res., 2013, 239, 27-30.
[33]
Sikora-Polaczek, M.; Bielak-Zmijewska, A.; Sikora, E. [Molecular and cellular mechanisms of curcumin action--beneficial effect on organism]. Postepy Biochem., 2011, 57(1), 74-84.
[34]
Tizabi, Y.; Hurley, L.L.; Qualls, Z.; Akinfiresoye, L. Relevance of the anti-inflammatory properties of curcumin in neurodegenerative diseases and depression. Molecules, 2014, 19(12), 20864-20879.
[35]
Alladi, P.; Mahadevan, A.; Yasha, T.; Raju, T.; Shankar, S.; Muthane, U. Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of Parkinson’s disease. Neuroscience, 2009, 159(1), 236-245.
[36]
Venigalla, M.; Gyengesi, E.; Munch, G. Curcumin and Apigenin - novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease. Neural Regen. Res., 2015, 10(8), 1181-1185.
[37]
Rao, M. Nitric oxide scavenging by curcuminoids. J. Pharm. Pharmacol., 1997, 49(1), 105-107.
[38]
Masuda, T.; Hidaka, K.; Shinohara, A.; Maekawa, T.; Takeda, Y.; Yamaguchi, H. Chemical studies on antioxidant mechanism of curcuminoid: Analysis of radical reaction products from curcumin. J. Agric. Food Chem., 1999, 47(1), 71-77.
[39]
Balogun, E.; Hoque, M.; Gong, P.; Killeen, E.; Green, C.; Foresti, R.; Alam, J.; Motterlini, R. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J., 2003, 371, 887-895.
[40]
Guimarães, M.R.; Leite, F.R.M.; Spolidorio, L.C.; Kirkwood, K.L.; Rossa, C. Curcumin abrogates LPS-induced pro-inflammatory cytokines in RAW 264.7 macrophages. Evidence for novel mechanisms involving SOCS-1,-3 and p38 MAPK. Arch. Oral Biol., 2013, 58(10), 1309-1317.
[41]
Morris, G.; Anderson, G.; Dean, O.; Berk, M.; Galecki, P.; Martin-Subero, M.; Maes, M. The glutathione system: A new drug target in neuroimmune disorders. Mol. Neurobiol., 2014, 50(3), 1059-1084.
[42]
Hu, Y.; Tang, J.S.; Hou, S.X.; Shi, X.X.; Qin, J.; Zhang, T.S.; Wang, X.J. Neuroprotective effects of curcumin alleviate lumbar intervertebral disc degeneration through regulating the expression of iNOS, COX-2, TGF-β1/2, MMP-9 and BDNF in a rat model. Mol. Med. Rep., 2017, 16(5), 6864-6869.
[43]
Kang, G.; Kong, P-J.; Yuh, Y-J.; Lim, S-Y.; Yim, S-V.; Chun, W.; Kim, S-S. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor. KAPPA. B bindings in bv2 microglial cells. J. Pharmacol. Sci., 2004, 94(3), 325-328.
[44]
Koeberle, A.; Northoff, H.; Werz, O. Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol. Cancer Ther., 2009, 8(8), 2348-2355.
[45]
Huang, M-T.; Lysz, T.; Ferraro, T.; Abidi, T.F.; Laskin, J.D.; Conney, A.H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res., 1991, 51(3), 813-819.
[46]
Raposo, C.; Nunes, A.K.; Luna, R.L.; Araújo, S.M.; da Cruz-Höfling, M.A.; Peixoto, C.A. Sildenafil (Viagra) protective effects on neuroinflammation: the role of iNOS/NO system in an inflammatory demyelination model. Mediators Inflamm., 2013, 2013, 321460.
[47]
Jiang, J.; Wang, W.; Sun, Y.J.; Hu, M.; Li, F.; Zhu, D.Y. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood–brain barrier damage. Eur. J. Pharmacol., 2007, 561(1-3), 54-62.
[48]
Jung, K.K.; Lee, H.S.; Cho, J.Y.; Shin, W.C.; Rhee, M.H.; Kim, T.G.; Kang, J.H.; Kim, S.H.; Hong, S.; Kang, S.Y. Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sci., 2006, 79(21), 2022-2031.
[49]
Austin, S.A.; Santhanam, A.V.; Hinton, D.J.; Choi, D.S.; Katusic, Z.S. Endothelial nitric oxide deficiency promotes Alzheimer’s disease pathology. J. Neurochem., 2013, 127(5), 691-700.
[50]
Morales, N.P.; Sirijaroonwong, S.; Yamanont, P.; Phisalaphong, C. Electron paramagnetic resonance study of the free radical scavenging capacity of curcumin and its demethoxy and hydrogenated derivatives. Biol. Pharm. Bull., 2015, 38(10), 1478-1483.
[51]
(a) Menon, V.P.; Sudheer, A.R. Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol., 2007, 595, 105-125.
(b) Choi, D.K.; Koppula, S.; Suk, K. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules (Basel, Switzerland), 2011, 16(2), 1021-1043.
[52]
He, H-J.; Wang, G-Y.; Gao, Y.; Ling, W-H.; Yu, Z-W.; Jin, T-R. Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice. World J. Diabetes, 2012, 3(5), 94.
[53]
Gupta, S.C.; Tyagi, A.K.; Deshmukh-Taskar, P.; Hinojosa, M.; Prasad, S.; Aggarwal, B.B. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch. Biochem. Biophys., 2014, 559, 91-99.
[54]
Balamurugan, A.; Akhov, L.; Selvaraj, G.; Pugazhenthi, S. Induction of antioxidant enzymes by curcumin and its analogues in human islets: implications in transplantation. Pancreas, 2009, 38(4), 454-460.
[55]
He, L.F.; Chen, H.J.; Qian, L.H.; Chen, G.Y.; Buzby, J.S. Curcumin protects pre-oligodendrocytes from activated microglia in vitro and in vivo. Brain Res., 2010, 1339, 60-69.
[56]
Cole, G.M.; Teter, B.; Frautschy, S.A. Neuroprotective effects of curcumin. Adv. Exp. Med. Biol., 2007, 595, 197-212.
[57]
Yu, Y.; Shen, Q.; Lai, Y.; Park, S.Y.; Ou, X.; Lin, D.; Jin, M.; Zhang, W. Anti-inflammatory effects of curcumin in microglial cells. Front. Pharmacol., 2018, 9, 386.
[58]
(a) Sezgin, Z.; Dincer, Y. Alzheimer’s disease and epigenetic diet. Neurochem. Int., 2014, 78, 105-116.
(b) Ullah, F.; Liang, A.; Rangel, A.; Gyengesi, E.; Niedermayer, G.; Münch, G. High bioavailability curcumin: An anti-inflammatory and neurosupportive bioactive nutrient for neurodegenerative diseases characterized by chronic neuroinflammation. Arch. Toxicol., 2017, 91(4), 1623-1634.
[59]
Cole, G.M.; Teter, B.; Frautschy, S.A. Neuroprotective effects of curcumin. In: The molecular targets and therapeutic uses of curcumin in health and disease; Springer, 2007; pp. 197-212.
[60]
Scapagnini, G.; Calabrese, V.; Motterlini, R.; Colombrita, C.; Alkon, D. Use of curcumin derivatives or CAPE in the manufacture
of a medicament for the treatment of neuroprotective disorders.
WO2004075883A1, September 10, 2004.
[61]
Eckert, G.P.; Renner, K.; Eckert, S.H.; Eckmann, J.; Hagl, S.; Abdel-Kader, R.M.; Kurz, C.; Leuner, K.; Muller, W.E. Mitochondrial dysfunction-A pharmacological target in Alzheimer’s disease. Mol. Neurobiol., 2012, 46(1), 136-150.
[62]
Chen, H.; Detmer, S.A.; Ewald, A.J.; Griffin, E.E.; Fraser, S.E.; Chan, D.C. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J. Cell Biol., 2003, 160(2), 189-200.
[63]
Wang, X.; Su, B.; Fujioka, H.; Zhu, X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. Am. J. Pathol., 2008, 173(2), 470-482.
[64]
Eckert, G.P.; Schiborr, C.; Hagl, S.; Abdel-Kader, R.; Müller, W.E.; Rimbach, G.; Frank, J. Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochem. Int., 2013, 62(5), 595-602.
[65]
Zhu, Y.G.; Chen, X.C.; Chen, Z.Z.; Zeng, Y.Q.; Shi, G.B.; Su, Y.H.; Peng, X. Curcumin protects mitochondria from oxidative damage and attenuates apoptosis in cortical neurons. Acta Pharmacol. Sin., 2004, 25, 1606-1612.
[66]
Ventura-Clapier, R.; Garnier, A.; Veksler, V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1α. Cardiovasc. Res., 2008, 79(2), 208-217.
[67]
Boyanapalli, S.S.; Kong, A.N.T. “Curcumin, the King of Spices”: Epigenetic regulatory mechanisms in the prevention of cancer, neurological, and inflammatory diseases. Curr. Pharmacol. Rep., 2015, 1(2), 129-139.
[68]
Chen, K.L.; Wang, S.S.; Yang, Y.Y.; Yuan, R.Y.; Chen, R.M.; Hu, C.J. The epigenetic effects of amyloid-β 1-40 on global DNA and neprilysin genes in murine cerebral endothelial cells. Biochem. Biophys. Res. Commun., 2009, 378(1), 57-61.
[69]
Wada, T.T.; Araki, Y.; Sato, K.; Aizaki, Y.; Yokota, K.; Kim, Y.T.; Oda, H.; Kurokawa, R.; Mimura, T. Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Biochem. Biophys. Res. Commun., 2014, 444(4), 682-686.
[70]
Yun, J.M.; Jialal, I.; Devaraj, S. Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J. Nutr. Biochem., 2011, 22(5), 450-458.
[71]
Miller, G. A role for epigenetics in cognition. Science, 2010, 329(5987), 27-27.
[72]
Sun, M.; Estrov, Z.; Ji, Y.; Coombes, K.R.; Harris, D.H.; Kurzrock, R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther., 2008, 7(3), 464-473.
[73]
Mohamed, T.; Shakeri, A.; Rao, P.P. Amyloid cascade in Alzheimer’s disease: Recent advances in medicinal chemistry. Eur. J. Med. Chem., 2016, 113, 258-272.
[74]
Wang, J.; Yu, J.T.; Tan, M.S.; Jiang, T.; Tan, L. Epigenetic mechanisms in Alzheimer’s disease: Implications for pathogenesis and therapy. Ageing Res. Rev., 2013, 12(4), 1024-1041.
[75]
Chouliaras, L.; Mastroeni, D.; Delvaux, E.; Grover, A.; Kenis, G.; Hof, P.R.; Steinbusch, H.W.; Coleman, P.D.; Rutten, B.P.; van den Hove, D.L. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer’s disease patients. Neurobiol. Aging, 2013, 34(9), 2091-2099.
[76]
Cristovao, J.S.; Santos, R. Metals and neuronal metal binding proteins implicated in Alzheimer’s disease. Oxid. Med. Cell. Longev., 2016, 2016, 9812178.
[77]
Venigalla, M.; Sonego, S.; Gyengesi, E.; Sharman, M.J.; Munch, G. Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease. Neurochem. Int., 2015, 95, 63-74.
[78]
Bassani, T.B.; Turnes, J.M.; Moura, E.L.; Bonato, J.M.; Cóppola-Segovia, V.; Zanata, S.M.; Oliveira, R.M.; Vital, M.A. Effects of curcumin on short-term spatial and recognition memory, adult neurogenesis and neuroinflammation in a streptozotocin-induced rat model of dementia of Alzheimer’s type. Behav. Brain Res., 2017, 335, 41-54.
[79]
Siddique, Y.H.; Naz, F.; Jyoti, S. Effect of curcumin on lifespan, activity pattern, oxidative stress, and apoptosis in the brains of transgenic Drosophila model of Parkinson’s disease. BioMed Res. Int., 2014, 2014, 606928.
[80]
Mogi, M.; Harada, M.; Narabayashi, H.; Inagaki, H.; Minami, M.; Nagatsu, T. Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci. Lett., 1996, 211(1), 13-16.
[81]
Urdinguio, R.G.; Sanchez-Mut, J.V.; Esteller, M. Epigenetic mechanisms in neurological diseases: Genes, syndromes, and therapies. Lancet Neurol., 2009, 8(11), 1056-1072.
[82]
Mythri, R.B.; Bharath, M.M. Curcumin: A potential neuroprotective agent in Parkinson’s disease. Curr. Pharm. Des., 2012, 18(1), 91-99.
[83]
(a) Aquilano, K.; Baldelli, S.; Rotilio, G.; Ciriolo, M.R. Role of nitric oxide synthases in Parkinson’s disease: A review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem. Res., 2008, 33(12), 2416-2426.
(b) Sharma, N.; Sharma, S.; Nehru, B. Curcumin protects dopaminergic neurons against inflammation-mediated damage and improves motor dysfunction induced by single intranigral lipopolysaccharide injection. Inflammopharmacology, 2017, 25(3), 351-368.
[84]
Cui, Q.; Li, X.; Zhu, H. Curcumin ameliorates dopaminergic neuronal oxidative damage via activation of the Akt/Nrf2 pathway. Mol. Med. Rep., 2016, 13(2), 1381-1388.
[85]
Wang, J.; Du, X.X.; Jiang, H.; Xie, J.X. Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappaB modulation in MES23. 5 cells. Biochem. Pharmacol., 2009, 78(2), 178-183.
[86]
Yu, S.; Zheng, W.; Xin, N.; Chi, Z.H.; Wang, N.Q.; Nie, Y.X.; Feng, W.Y.; Wang, Z.Y. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res., 2010, 13(1), 55-64.
[87]
Song, J.X.; Sze, S.C.; Ng, T.B.; Lee, C.K.; Leung, G.P.; Shaw, P.C.; Tong, Y.; Zhang, Y.B. Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J. Ethnopharmacol., 2012, 139(3), 698-711.
[88]
(a) Abdolahi, M.; Yavari, P.; Honarvar, N.M.; Bitarafan, S.; Mahmoudi, M.; Saboor-Yaraghi, A.A. Molecular mechanisms of the action of vitamin A in Th17/Treg axis in multiple sclerosis. J. Mol. Neurosci., 2015, 57(4), 605-613.
(b) Honarvar, N.M.; Harirchian, M.H.; Abdolahi, M.; Abedi, E.; Bitarafan, S.; Koohdani, F.; Siassi, F.; Sahraian, M.A.; Chahardoli, R.; Zareei, M. Retinyl palmitate supplementation modulates T-bet and interferon gamma gene expression in multiple sclerosis patients. J. Mol. Neurosci., 2016, 59(3), 360-365.
[89]
Honarvar, N.M.; Saedisomeolia, A.; Abdolahi, M.; Shayeganrad, A.; Sangsari, G.T.; Rad, B.H.; Muench, G. Molecular anti-inflammatory mechanisms of retinoids and carotenoids in Alzheimer’s disease: A review of current evidence. J. Mol. Neurosci., 2017, 61(3), 289-304.
[90]
Dorosty-Motlagh, A.R.; Honarvar, N.M.; Sedighiyan, M.; Abdolahi, M. The molecular mechanisms of vitamin A deficiency in multiple sclerosis. J. Mol. Neurosci., 2016, 60(1), 82-90.
[91]
Mastronardi, F.G.; Noor, A.; Wood, D.D.; Paton, T.; Moscarello, M.A. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J. Neurosci. Res., 2007, 85(9), 2006-2016.
[92]
Xie, L.; Li, X.K.; Funeshima-Fuji, N.; Kimura, H.; Matsumoto, Y.; Isaka, Y.; Takahara, S. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int. Immunopharmacol., 2009, 9(5), 575-581.
[93]
Bondan, E.; Cardoso, C.; Martins, M.D.F. Curcumin decreases astrocytic reaction after gliotoxic injury in the rat brainstem. Arq. Neuropsiquiatr., 2017, 75(8), 546-552.
[94]
Bachmeier, B.E.; Mohrenz, I.V.; Mirisola, V.; Schleicher, E.; Romeo, F.; Höhneke, C.; Jochum, M.; Nerlich, A.G.; Pfeffer, U. Curcumin downregulates the inflammatory cytokines CXCL1 and-2 in breast cancer cells via NFκB. Carcinogenesis, 2008, 29(4), 779-789.
[95]
Kanakasabai, S.; Casalini, E.; Walline, C.C.; Mo, C.; Chearwae, W.; Bright, J.J. Differential regulation of CD4(+) T helper cell responses by curcumin in experimental autoimmune encephalomyelitis. J. Nutr. Biochem., 2012, 23(11), 1498-1507.
[96]
Choi, K.H.; Park, J.W.; Kim, H.Y.; Kim, Y.H.; Kim, S.M.; Son, Y.H.; Park, Y.C.; Eo, S.K.; Kim, K. Cellular factors involved in CXCL8 expression induced by glycated serum albumin in vascular smooth muscle cells. Atherosclerosis, 2010, 209(1), 58-65.
[97]
Xie, L.; Li, X.K.; Takahara, S. Curcumin has bright prospects for the treatment of multiple sclerosis. Int. Immunopharmacol., 2011, 11(3), 323-330.
[98]
Hong, J.; Bose, M.; Ju, J.; Ryu, J.H.; Chen, X.; Sang, S.; Lee, M.J.; Yang, C.S. Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: Effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis, 2004, 25(9), 1671-1679.
[99]
Aranami, T.; Yamamura, T. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int., 2008, 57(2), 115-120.
[100]
Abdolahi, M.; Yavari, P.; Honarvar, N.M.; Bitarafan, S.; Mahmoudi, M.; Saboor-Yaraghi, A.A. Molecular mechanisms of the action of vitamin A in Th17/Treg axis in multiple sclerosis. J. Mol. Neurosci., 2015, 57(4), 605-613.
[101]
Zhang, H.J.; Xing, Y.Q.; Jin, W.; Li, D.; Wu, K.; Lu, Y. Effects of curcumin on interleukin-23 and interleukin-17 expression in rat retina after retinal ischemia-reperfusion injury. Int. J. Clin. Exp. Pathol., 2015, 8(8), 9223-9231.
[102]
Qureshi, M.; Al-Suhaimi, E.A.; Wahid, F.; Shehzad, O.; Shehzad, A. Therapeutic potential of curcumin for multiple sclerosis. Neurol. Sci., 2017, 39(2), 207-214.